Despite a cash stockpile of roughly $36bn on hand at the end of the second quarter, Gilead Sciences Inc.'s announced plan to acquire Kite Pharma Inc. Aug. 28 for $11.9bn – structured as a mix of cash, senior unsecured notes and bank financing – likely forestalls it from undertaking any further large-scale M&A in the near term.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?